Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: A unifying concept in anti-hormone resistance

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 387-398

  Balaburski, Gregor M ^a   Dardes, Rita C ^b   Johnson, Michael ^c   Haddad, Bassem ^c   Zhu, Fang ^a   Ross, Eric A ^a   Sengupta, Surojeet ^c   Klein Szanto, Andres ^a   Liu, Hong ^d   Lee, Eun Sook ^d   Kim, Helen ^c   Jordan, V Craig ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c GEORGETOWN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Osteoporosis; Raloxifene; Tamoxifen

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; RALOXIFENE; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GRAFT; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARIECTOMY; PARADOXICAL DRUG REACTION; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; CARCINOMA; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; DRUG RESISTANCE; DRUG SCREENING; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954148994     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000687     Document Type: Article

References (53)

1. Jordan VC: Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell 5: 207-213, 2004. (Pubitemid 38402112)
2. Tamoxifen for early breast cancer: An overview of the randomised trials. Early breast cancer trialists' collaborative group. Lancet 351: 1451-1467, 1998.
3. Jordan VC: Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7: 46-53, 2007. (Pubitemid 46020846)
4. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388, 1998.
5. Gottardis MM and Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183-5187, 1988.
6. Gottardis MM, Wagner RJ, Borden EC and Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49: 4765-4769, 1989.
7. Black LJ, Jones CD and Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32: 1031-1036, 1983.
8. Clemens JA, Bennett DR, Black LJ and Jones CD: Effects of a new antiestrogen, keoxifene (ly156758), on growth of carcinogen-induced mammary tumors and on lH and prolactin levels. Life Sci 32: 2869-2875, 1983.
9. Gottardis MM and Jordan VC: Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea induced rat mammary carcinoma model. Cancer Res 47: 4020-4024, 1987. (Pubitemid 17108463)
10. Jordan VC, Phelps E and Lindgren JU: Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31-35, 1987. (Pubitemid 18038542)
11. Jordan VC: Chemosuppression of breast cancer with tamoxifen: Laboratory evidence and future clinical investigations. Cancer Invest 6: 589-595, 1988.
12. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (more) investigators. JAMA 282: 637-645, 1999.
13. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the more randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281: 2189-2197, 1999.
14. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741, 2006.
15. Barrett-Connor E, Mosca L, Collins P, et al: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125-137, 2006. (Pubitemid 44050394)
16. Martino S, Cauley JA, Barrett-Connor E, et al: Continuing outcomes relevant to evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96: 1751-1761, 2004.
17. Wolf DM and Jordan VC: A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 127: 23-33, 1993.
18. Yao K, Lee ES, Bentrem DJ, et al: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036, 2000.
19. O'Regan RM, Osipo C, Ariazi E, et al: Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 12: 2255-2263, 2006.
20. Liu H, Lee ES, Gajdos C, et al: Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95: 1586-1597, 2003.
21. Song RX, Mor G, Naftolin F, et al: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723, 2001.
22. Song RX, Zhang Z, Mor G and Santen RJ: Down-regulation of BCL-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 10: 667-678, 2005. (Pubitemid 40896672)
23. Lewis JS, Meeke K, Osipo C, et al: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759, 2005. (Pubitemid 41782284)
24. Lewis JS, Osipo C, Meeke K and Jordan VC: Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94: 131-141, 2005. (Pubitemid 40614526)
25. Kennedy BJ: Diethylstilbestrol versus testosterone propionate therapy in advanced breast cancer. Surg Gynecol Obstet 120: 1246-1250, 1965.
26. Haddow A, Watkinson JM, Paterson E and Koller PC: Influence of synthetic oestrogens on advanced malignant disease. Br Med J 2: 393-398, 1944.
27. Lonning PE, Taylor PD, Anker G, et al: High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116, 2001. (Pubitemid 32744491)
28. Ellis MJ, Gao F, Dehdashti F, et al: Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA 302: 774-780, 2009.
29. Lins AM, Micka KA, Sprecher CJ, et al: Development and population study of an eight-locus short tandem repeat (STR) multiplex system. J Forensic Sci 43: 1168-1180, 1998. (Pubitemid 28554814)
30. Jamerson MH, Johnson MD, Korsmeyer SJ, Furth PA and Dickson RB: Bax regulates c-myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice. Br J Cancer 91: 1372-1379, 2004.
31. Labarca C and Paigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102: 344-352, 1980. (Pubitemid 10115803)
32. Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B and Jordan VC: Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 85: 498-506, 2002. (Pubitemid 34651892)
33. Robinson SP and Jordan VC: Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758-1762, 1989.
34. O'Regan RM, Cisneros A, England GM, et al: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552-1558, 1998.
35. Ariazi EA, Lewis-Wambi JS, Gill SD, et al: Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. J Steroid Biochem Mol Biol 102: 128-138, 2006.
36. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC and Mertz JE: Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the erbb2/her2 signaling pathway. Mol Cancer Res 5: 71-85, 2007.
37. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM and Lippman ME: Greb 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92: 141-149, 2005.
38. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-(delta)(delta)ct method. Methods 25: 402-408, 2001.
39. Ariazi EA, Clark GM and Mertz JE: Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62: 6510-6518, 2002.
40. Pink JJ and Jordan VC: Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330, 1996. (Pubitemid 26154081)
41. Rae JM, Creighton CJ, Meck JM, Haddad BR and Johnson MD: MDA-MB-435 cells are derived from M14 melanoma cells - loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104: 13-19, 2007.
42. Jiang SY, Langan-Fahey SM, Stella AL, McCague R and Jordan VC: Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of anti-estrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 6: 2167-2174, 1992.
43. Brooks SC, Locke ER and Soule HD: Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248: 6251-6253, 1973.
44. Lonning PE: Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncol 48: 1092-1101, 2009.
45. Osipo C, Gajdos C, Liu H, Chen B and Jordan VC: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95: 1597-1608, 2003. (Pubitemid 37455927)
46. Robertson JF, Llombart-Cussac A, Rolski J, et al: Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the first study. J Clin Oncol 27: 4530-4535, 2009.
47. Kokontis J, Takakura K, Hay N and Liao S: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54: 1566-1573, 1994. (Pubitemid 24106424)
48. Umekita Y, Hiipakka RA, Kokontis JM and Liao S: Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93: 11802-11807, 1996.
49. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM and Liao S: Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 65: 2082-2084, 2005. (Pubitemid 40490112)
50. Abrahamsson PA: Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol (In press).
51. Jordan VC: The 38th David A. Karnofsky lecture: The paradoxical actions of estrogen in breast cancer - survival or death? J Clin Oncol 26: 3073-3082, 2008.
52. Maximov PY, Lewis-Wambi JS and Jordan VC: The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Curr Signal Transduct Ther 4: 88-102, 2009.
53. Jordan VC: A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: The origins of targeted therapy and chemoprevention. Cancer Res 69: 1243-1254, 2009.